Posted by Michael Wonder on 09 Jun 2024
US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus vaccine for adults aged 50-59 at increased risk
7 June 2024 - Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe respiratory syncytial virus outcomes.
GSK today announced that the US FDA has approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of respiratory syncytial virus lower respiratory tract disease in adults 50 through 59 years of age who are at increased risk.
